Salbutamol active pharmaceutical ingredient (API) Market Report 2026

Salbutamol active pharmaceutical ingredient (API) Market Overview

• Salbutamol active pharmaceutical ingredient (API) market size has reached to $3.05 billion in 2025 • Expected to grow to $4.14 billion in 2030 at a compound annual growth rate (CAGR) of 6.3% • Growth Driver: Increasing Incidence Of Respiratory Diseases Fueling The Growth Of The Market Due To Rising Air Pollution And Lung Health Complications • Market Trend: Eco-Friendly Inhalers Drive Sustainable Respiratory Care • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Salbutamol active pharmaceutical ingredient (API) Market?

Salbutamol active pharmaceutical ingredient (API) is the pure, pharmacologically active substance responsible for producing the intended therapeutic effect of medications used to treat respiratory conditions. It is used by pharmaceutical manufacturers as the core compound in the formulation of finished drug products such as tablets, inhalers, and syrups. The main types of salbutamol active pharmaceutical ingredient (API) are salbutamol sulfate and levalbuterol hydrochloride. Salbutamol sulfate is the sulfate salt form of salbutamol, a fast-acting bronchodilator used to relieve symptoms of asthma and other obstructive airway conditions by relaxing the muscles in the airways. The formulation types include inhalation solutions, tablet formulations, syrup formulations, and others, and are distributed through channels such as hospital pharmacies, retail pharmacies, and online pharmacies. They are used for applications including asthma, chronic obstructive pulmonary disease (COPD), bronchospasm, and others, catering to end users, pharmaceutical companies, research laboratories, and others.

What Is The Salbutamol active pharmaceutical ingredient (API) Market Growth Forecast?

The salbutamol active pharmaceutical ingredient (api) market size is expected to see strong growth in the next few years. It will grow to $4.14 billion in 2030 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to technological advancements in api synthesis, expansion of generic and branded respiratory drugs, rising investment in r&d for advanced delivery formulations, increasing regulatory approvals and certifications, integration of smart manufacturing and digital monitoring systems. Major trends in the forecast period include rising demand for salbutamol api in respiratory drug formulations, expansion of inhalation and oral delivery methods, growing focus on high-purity and quality-compliant api production, increase in research and development for asthma and copd treatments, rising online and retail pharmacy distribution channels.

Global Salbutamol active pharmaceutical ingredient (API) Market Segmentation

1) By Type: Salbutamol Sulfate, Levalbuterol Hydrochloride 2) By Formulation Type: Inhalation Solutions, Tablet Formulations, Syrup Formulations, Other Delivery Methods 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 4) By Application: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Bronchospasm, Other Applications 5) By End-User: Pharmaceutical Companies, Research Laboratories, Other End Users Subsegments: 1) By Salbutamol Sulfate: Inhalation Powder, Inhalation Solution, Oral Tablets, Oral Syrup, Injectable Form 2) By Levalbuterol Hydrochloride: Inhalation Solution, Metered Dose Inhaler (MDI), Oral Solution, Nebulizer Solution

What Is The Driver Of The Salbutamol active pharmaceutical ingredient (API) Market?

The increasing incidence of respiratory diseases is expected to propel the growth of the salbutamol active pharmaceutical ingredient (API) market going forward. Respiratory conditions are illnesses that impact the lungs and airways, leading to difficulty in breathing and reduced oxygen intake. It includes asthma, chronic obstructive pulmonary disease (COPD), pneumonia, bronchitis, and lung infections. The growing prevalence of respiratory conditions is due to rising air pollution, which increases the exposure to harmful pollutants that irritate the airways and worsen lung function. Salbutamol active pharmaceutical ingredient (API) aids in treating respiratory diseases by opening up the airways and easing breathing. It offers fast relief from symptoms such as wheezing and shortness of breath, improving respiratory function and patient well-being. For instance, in November 2024, according to the Australian Bureau of Statistics, an Australia-based government agency, asthma accounted for 2.5% of the total disease burden and 35% of the burden from all respiratory conditions in 2023, and it was the leading cause of disease burden among children aged 1–9 years. Therefore, increasing respiratory disease incidence is driving the growth of the salbutamol active pharmaceutical ingredient (API) industry.

Key Players In The Global Salbutamol active pharmaceutical ingredient (API) Market

Major companies operating in the salbutamol active pharmaceutical ingredient (api) market are Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Lupin Limited, Amphastar Pharmaceuticals Inc., Neuland Laboratories Ltd., Supriya Lifescience Ltd., Lusochimica S.p.A., Intas Pharmaceuticals Ltd., Olon S.p.A., VIVAN Life Sciences, Vamsi Labs Ltd., Aarti Pharmalabs Ltd., Chemcopia, Cerata Pharma, Hetero Labs Ltd., Granules India Ltd., MSN Laboratories Ltd., Macleods Pharmaceuticals Ltd., Zydus Lifesciences Ltd., Glenmark Pharmaceuticals Ltd., Ipca Laboratories Ltd., Alembic Pharmaceuticals Ltd., Indoco Remedies Ltd., Jubilant Pharmova Ltd., Laurus Labs Ltd., Teva Active Pharmaceutical Ingredients, Cambrex Corporation, Zhejiang Supor Pharmaceuticals Co. Ltd., Shandong Xinhua Pharmaceutical Co. Ltd., Hubei Gedian Humanwell Pharmaceutical Co. Ltd.

Global Salbutamol active pharmaceutical ingredient (API) Market Trends and Insights

Major companies operating in the salbutamol active pharmaceutical ingredient (API) market are focusing on developing innovative drug formulations, such as eco-friendly inhalers, to meet environmental standards and offer sustainable treatment options. Eco-friendly inhalers are respiratory devices that use propellants with low global warming potential or propellant-free systems, such as dry powder inhalers. For instance, in November 2023, GSK plc, a UK-based pharmaceutical company, announced the progression to Phase III trials of its low-carbon Ventolin inhaler, which uses a next-generation propellant to reduce emissions by 90%. Ventolin is the brand name for inhalers containing salbutamol (also known as albuterol), the medication responsible for opening up the airways in the lungs and providing relief from asthma and other respiratory conditions. The sustainability initiative focuses on changing the propellant used in the inhaler to reduce its carbon footprint, but the active medication delivered, the salbutamol API, remains the same.

What Are Latest Mergers And Acquisitions In The Salbutamol active pharmaceutical ingredient (API) Market?

In April 2024, Teva Pharmaceutical Industries Ltd., an Israel-based pharmaceutical company, partnered with Launch Therapeutics to advance the development of TEV-248, a dual-action asthma rescue inhaler combining an inhaled corticosteroid (ICS) and a short-acting beta-agonist (SABA). With this partnership, Teva and Launch Therapeutics aim to accelerate clinical development, improve patient access, and support regulatory progress for this next-generation rescue therapy. Teva also entered a strategic development-funding agreement with Abingworth to further support the program’s advancement. Launch Therapeutics is a U.S.-based clinical development accelerator focused on advancing innovative late-stage therapies.

Regional Insights

North America was the largest region in the salbutamol active pharmaceutical ingredient (API) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Salbutamol active pharmaceutical ingredient (API) Market?

The salbutamol active pharmaceutical ingredient (API) market consists of sales of nebulizer solutions, raw salbutamol powder, and injectable salbutamol formulations. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Salbutamol active pharmaceutical ingredient (API) Market Report 2026?

The salbutamol active pharmaceutical ingredient (api) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the salbutamol active pharmaceutical ingredient (api) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.